Literature DB >> 25366168

A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients.

Na Xu1, Li Ding, Changxin Yin, Xuan Zhou, Lin Li, Yulin Li, Qisi Lu, Xiao-li Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25366168     DOI： 10.1007/s00277-014-2248-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

Review 1.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

2.  Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Authors:  Carla Al Assaf; Florence Van Obbergh; Johan Billiet; Els Lierman; Timothy Devos; Carlos Graux; Anne-Sophie Hervent; Jan Emmerechts; Thomas Tousseyn; Pascale De Paepe; Petros Papadopoulos; Lucienne Michaux; Peter Vandenberghe
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

3.  Absence of CALR mutations in JAK2-negative polycythemia.

Authors:  Aurélie Chauveau; Olivier Nibourel; Sylvie Tondeur; Damien Luque Paz; Olivier Mansier; Franciane Paul; Mathieu Wemeau; Claude Preudhomme; Eric Lippert; Valérie Ugo
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

4.  Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.

Authors:  Munazza Rashid; Rifat Zubair Ahmed; Shariq Ahmed; Muhammad Nadeem; Nuzhat Ahmed; Tahir Sultan Shamsi
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-09       Impact factor: 0.900

Review 5.  JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.

Authors:  Naseema Gangat; Natasha Szuber; Animesh Pardanani; Ayalew Tefferi
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.